Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
8.66
+0.16 (1.88%)
At close: Sep 26, 2025, 4:00 PM EDT
8.74
+0.08 (0.92%)
After-hours: Sep 26, 2025, 6:47 PM EDT
Anavex Life Sciences Employees
Anavex Life Sciences had 42 employees as of September 30, 2024. The number of employees increased by 2 or 5.00% compared to the previous year.
Employees
42
Change (1Y)
2
Growth (1Y)
5.00%
Revenue / Employee
n/a
Profits / Employee
-$1,146,905
Market Cap
743.84M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVXL News
- 18 days ago - Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial - GlobeNewsWire
- 25 days ago - Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 - GlobeNewsWire
- 4 weeks ago - Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease - GlobeNewsWire
- 6 weeks ago - Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 - GlobeNewsWire
- 2 months ago - Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease - GlobeNewsWire